(Q38711504)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Chemotherapy for Muscle-Invasive Bladder Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Patrizia Trenta

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Linda Cerbone

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Cora N Sternberg

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

1 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

Current Treatment Options in Oncology

6 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26810055%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11864-015-0376-y

6 March 2020

exact match

0 references

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

The present and future burden of urinary bladder cancer in the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

International variations in bladder cancer incidence and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

The costs of non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Update on chemotherapy for advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Chemotherapy of urothelial tract tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Mutational landscape and significance across 12 major cancer types

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0376-Y

Advanced Bladder Cancer (Stages pT3b, pT4a, pN1 and pN2): Improved Survival after Radical Cystectomy and 3 Adjuvant Cycles of Chemotherapy. Results of a Controlled Prospective Study

21 January 2018

1 reference

12 December 2020

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

12 December 2020

Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2

1 reference

12 December 2020

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

1 reference

12 December 2020

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

1 reference

12 December 2020

Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the Bladder

1 reference

12 December 2020

Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update

1 reference

12 December 2020

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, an

1 reference

12 December 2020

Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study

1 reference

12 December 2020

Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group

1 reference

12 December 2020

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

1 reference

12 December 2020

A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.

1 reference

12 December 2020

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

12 December 2020

Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era

1 reference

12 December 2020

Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial

1 reference

12 December 2020

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

12 December 2020

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

12 December 2020

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

12 December 2020

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

1 reference

12 December 2020

Neoadjuvant chemotherapy in invasive bladder cancer. Trial design

1 reference

12 December 2020